Key result
Recombinant human tissue kallikrein-1 targets a ~36-fold B2 receptor surge to boost ischemic brain perfusion.
Why the study?
Does rKLK1 improve clinical outcomes and prevent recurrence in patients with acute ischemic stroke?
Does rKLK1 improve clinical outcomes and prevent recurrence in patients with acute ischemic stroke?
Answers are grounded in this paper and cite their sources.
rKLK1 offers a promising therapeutic strategy for acute ischemic stroke by enhancing brain perfusion and potentially reducing recurrence, warranting further investigation in ongoing trials.
Novel strategies are needed for the treatment of acute ischemic stroke when revascularization therapies are not clinically appropriate or are unsuccessful. rKLK1 (recombinant human tissue kallikrein-1), a bradykinin-producing enzyme, offers a promising potential solution. In animal studies of acute stroke, there is a marked 36-fold increase in bradykinin B2 receptor on brain endothelial cells of the ischemic region. Due to this environment, rKLK1-generated bradykinin will exert a potent local vasodilation and increase brain perfusion via 3 synergistic signaling pathways downstream to the B2 receptor. Because of its preferential effect on ischemic tissue, systemic adverse effects such as hypotension are avoided with proper dosing. In addition, with initial vasodilation through recruitment of preexisting collaterals, rKLK1 promotes long-term benefit of brain perfusion by promoting new collateral formation. With an extended course of therapy for weeks after acute ischemic stroke, these multifaceted effects may also reduce the risk of stroke recurrence. A prior phase II trial demonstrated a favorable impact on clinical outcomes and recurrent strokes, particularly among patients who were not eligible for mechanical thrombectomy. A phase II/III trial has launched in this population, though opportunities for combination revascularization therapies deserve further investigation.
No takes yet. Share an insight, caveat, or question.
Kasner et al. (2025) conducted a review in Acute ischemic stroke. Recombinant human tissue kallikrein-1 (rKLK1) was evaluated. Recombinant human tissue kallikrein-1 exploits a 36-fold increase in B2 receptors in ischemic regions to increase brain perfusion, with a phase II/III trial currently underway for acute stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: